title: [Treatment of tuberculosis in patients with comorbidities].
abstract: Early detection and appropriate treatment are the keys to tuberculosis control. In particular, providing appropriate treatment for tuberculosis in patients with HIV infection, rheumatoid arthritis (RA), chronic hepatic disease, or renal failure necessitating hemodialysis, and taking appropriate measures against adverse reactions to antituberculosis drugs are issues of critical importance. This mini-symposium, four experts explained the current status of "treatment of tuberculosis in patients with comorbidities" and proposed measures to address these problems. Dr. Aoki talked about "HIV infection complicated by tuberculosis." To the next, Dr. Yoshinaga gave a talk on "treatment of tuberculosis in RA patients receiving biological agents. Further, Dr. Sasaki lectured on "tuberculosis in patients with hepatic disease/impairment". Lastly, Dr. Takamori gave a lecture on "tuberculosis in patients with renal disease and those on hemodialysis. Tuberculosis patients often have some underlying diseases, and adverse reactions caused by antituberculosis drugs, such as hepatic and renal impairments, are matters of concern. I believe that this mini-symposium has provided useful information for physicians engaged in tuberculosis treatment and for many other healthcare professionals as well.
authors.affiliation: National Hospital Organization Ehime National Hospital, Japan. mabe@ehime-nh.go.jp
authors.forename: Masahiro
authors.initials: M
authors.lastname: Abe
authors.affiliation: Tokyo Metropolitan Health and Treatment Corporation Tama-Hokubu Medical Center, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Fujita
mesh_terms: D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000453:epidemiology; D015897:Comorbidity; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D016867:Immunocompromised Host; D007564:Japan / Q000453:epidemiology; D007674:Kidney Diseases / Q000453:epidemiology / Q000628:therapy; D008107:Liver Diseases / Q000453:epidemiology / Q000628:therapy; D011379:Prognosis; D006435:Renal Dialysis / Q000009:adverse effects; D012306:Risk; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000209:etiology
chemical_list: D044966:Anti-Retroviral Agents; D018501:Antirheumatic Agents; D000995:Antitubercular Agents